文献速递浆细胞疾病

靶向ABCD1-ACOX1-MET/IGF1R轴抑制多发性骨髓瘤

Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma.
PubMed 文献 · Leukemia · 2025-01-30

本研究揭示细胞内极长链脂肪酸(VLCFA)水平调控多发性骨髓瘤(MM)化疗药物细胞毒性。抑制VLCFA降解(通过抑制过氧化物酶体酰基辅酶A氧化酶1,ACOX1)可增强硼替佐米、卡非佐米和来那度胺的细胞毒性,口服ACOX1抑制剂与硼替佐米协同抑制硼替佐米耐药MM异种移植瘤生长。机制上,ACOX1抑制促进含VLCFA脑苷脂积累,选择性抑制MET和IGF1R与质膜信号平台的关联而不破坏平台完整性。

要点

  • 抑制VLCFA生物合成降低硼替佐米对MM细胞的杀伤,抑制VLCFA降解则增强硼替佐米、卡非佐米和来那度胺的细胞毒性。
  • 口服ACOX1抑制剂与硼替佐米协同抑制小鼠硼替佐米耐药MM异种移植瘤生长。
  • ACOX1抑制促进含VLCFA脑苷脂积累,选择性抑制MET和IGF1R与质膜信号平台关联而不破坏平台完整性。

核心结论

  • MM细胞存在特定的代谢脆弱性,VLCFA代谢与MET和IGF1R活性调控之间存在可靶向的轴。

研究设计与样本

  • 研究采用MM细胞和小鼠硼替佐米耐药MM异种移植瘤模型,评估VLCFA代谢调控对化疗药物细胞毒性的影响及ACOX1抑制剂与硼替佐米的联合效果。

主要发现

  • 抑制VLCFA生物合成降低硼替佐米引起的MM细胞死亡。
  • 抑制ACOX1增加硼替佐米、卡非佐米和来那度胺的细胞毒性。
  • 口服ACOX1抑制剂与硼替佐米协同抑制小鼠硼替佐米耐药MM异种移植瘤生长。
  • 遗传或药理抑制VLCFA降解升高VLCFA水平,降低MET和IGF1R两种激酶活性。
  • ACOX1抑制促进含VLCFA脑苷脂积累,改变MET和IGF1R与脑苷脂类似物的相互作用,选择性抑制这些激酶与质膜信号平台的关联而不破坏平台完整性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib. Conversely, inhibition of VLCFA degradation via suppression of peroxisomal acyl-CoA oxidase 1 (ACOX1) increased the cytotoxicity of bortezomib, its next-generation analog, carfilzomib, and the immunomodulatory agent lenalidomide. Furthermore, treatment with an orally available ACOX1 inhibitor cooperated with bortezomib in suppressing the growth of bortezomib-resistant MM xenografts in mice. Increased VLCFA levels caused by genetic or pharmacological inhibition of VLCFA degradation reduced the activity of two major kinases involved in MM pathogenesis, MET proto-oncogene (MET) and insulin-like growth factor 1 receptor (IGF1R). Mechanistically, inhibition of ACOX1 promoted the accumulation of VLCFA-containing cerebrosides, altered MET and IGF1R interaction with a cerebroside analog, and selectively inhibited the association of these kinases with the plasma membrane signaling platforms, importantly, without disrupting the platforms' integrity. Our study revealed a specific metabolic vulnerability of MM cells and identified a targetable axis linking VLCFA metabolism to the regulation of MET and IGF1R activity.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Han Z, Yan Z, Ma Z, et al. Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma. Leukemia. 2025. PMID: 39885295. doi:10.1038/s41375-025-02522-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。